Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595366 | 0.96 | CYP3A4 (0.46) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| SCHEMBL1727172 | 0.96 | CYP3A4 (0.46) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| Iodide SCHEMBL8728751 | 0.94 | CYP3A4 (0.44) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| Bromide SCHEMBL29496481 | 0.94 | CYP3A4 (0.44) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| Iodide SCHEMBL11355870 | 0.94 | CYP3A4 (0.44) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL29496457 | 0.94 | CYP3A4 (0.44) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| SCHEMBL5988443 | 0.92 | CYP3A4 (0.46) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| Acetic Acid SCHEMBL29452750 | 0.90 | CYP3A4 (0.41) | CYP3A4TDP1DRD1GABRA1GABRB2 | |
| SCHEMBL20873227 | 0.89 | GABRA1 (0.42) | GABRA1GABRB2TP53MGLLMAPT | |
| SCHEMBL29790848 | 0.87 | GABRA1 (0.44) | GABRA1GABRB2TP53MGLLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466988-B1 | OLIGOMERIZING CATALYST AND METHOD FOR PREPARING ETHYLENE OLIGOMER USING SAME | SK INNOVATION CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-11235315-B2 | Oligomerization catalyst and method for preparing ethylene oligomer using same | SK INNOVATION CO., LTD. (KR) | 2022-02-01 | — | — | US | disclosed |
| US-20190308178-A1 | Oligomerization Catalyst and Method for Preparing Ethylene Oligomer Using Same | SK INNOVATION CO, LTD. (KR) | 2019-10-10 | — | — | US | disclosed |
| EP-3466988-A1 | OLIGOMERIZING CATALYST AND METHOD FOR PREPARING ETHYLENE OLIGOMER USING SAME | SK Innovation Co., Ltd. (KR) | 2019-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11235315-B2 | Oligomerization catalyst and method for preparing ethylene oligomer using same | AP1M1, NOD2, NOD1 | CYP3A4 1114/4885TDP1 1927/4885DRD1 1267/4885 |
| US-20190308178-A1 | Oligomerization Catalyst and Method for Preparing Ethylene Oligomer Using Same | AP1M1, NOD2, NOD1 | CYP3A4 1208/4885TDP1 1943/4885DRD1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.